On January 31, 2025, Celltrion announced that the FDA approved its tocilizumab biosimilar, AVTOZMA® (tocilizumab-anoh), referencing Genentech’s ACTEMRA®.  Tocilizumab is a monoclonal antibody that can act as an interleukin-6 (IL-6) inhibitor to reduce inflammation in the body.  The FDA approved AVTOZMA® for subcutaneous injection or intravenous infusion for treatment of multiple diseases, including rheumatoid arthritis…